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Abstract Tuberous Sclerosis Complex (TSC) is a multi-
organ genetic disease caused by loss of function of either
the TSC1 (encodes hamartin) or TSC2 (encodes tuberin)
genes. Patients with TSC have benign tumors (hamartomas)
in multiple organs though brain involvement is typically the
most disabling aspect of the disease as very high rates of
neurodevelopmental disorders are seen. While first de-
scribed well over 120 years ago, recent advances have
transformed TSC into a prototypical disorder that exem-
plifies the methods and potential of molecular medicine.
This review will detail historical aspects of TSC and its
strong associations with neurodevelopmental disorders
focusing on epilepsy and autism. Finally, promising new
approaches for the treatment of epilepsy and autism in
patients with TSC as well as those in the general population
will be discussed.
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Introduction
While recognized as a specific disease for well over
125 years, TSC has continued to intrigue and frustrate
physicians, scientists and patients alike given its prominent
association with many organs of the body including brain,
heart, kidney, skin and lung. Brain involvement however is
most debilitating as intractable epilepsy, developmental
delay and autism are seen in many patients. These features
usually arise early in childhood and are typically resistant to
existing therapies. Despite these many challenges, research
over the past 15 years has flourished with seminal advances
that include cloning of the TSC1 and TSC2 genes,
identification of downstream signaling pathways, genera-
tion of relevant animal models and possibly even the
development of new rational therapies. TSC should not be
considered a rare disease. It has a worldwide incidence of
approximately 1:6,000 births [1] and many people with this
disorder have severe neurological manifestations [2].
Though it has been recognized as a distinct neurocutaneous
disease for many years with a close association between
epilepsy, autism, developmental delay and psychiatric
problems, the importance of TSC also lies as a prototypical
neurodevelopmental disorder. In this sense TSC serves as
an excellent example of the power of molecular based
technologies to define disease mechanisms. Advances in
TSC will continue and should offer further important
lessons for many genetic diseases affecting brain develop-
ment, epilepsy, cognition and social function.
Neurological manifestations
Epilepsy
Epilepsy is seen in up to 90% of all patients with TSC
during their lifetime [3]. This extraordinary prevalence
affects all aspects of brain dysfunction in TSC and highly
impacts the quality of life of these patients as well as their
families. Multiple seizures types are seen in TSC though
J Neurodevelop Disord (2009) 1:141–149
DOI 10.1007/s11689-009-9014-y
K. C. Ess
Department of Neurology, Vanderbilt Kennedy Center for
Research on Human Development, Tuberous Sclerosis Clinic,
Vanderbilt Children’s’ Hospital, Vanderbilt University,
2201 West End Avenue,
Nashville, TN 37240, USA
K. C. Ess (*)
Vanderbilt University Medical Center,
465 21st Ave. South, MRBIII, 6158, Nashville, TN 37232, USA
e-mail: kevin.ess@vanderbilt.educomplex partial and primary generalized seizures are the
most common. Of note, infantile spasms are seen up to 50–
60% of patients [4, 5] making TSC likely the most common
known genetic cause of these often devastating seizures.
Infantile spasms merit special attention given this high
prevalence but also because these seizures may be the first
manifestation of TSC in undiagnosed patients. Thus, all
children presenting with infantile spasms should undergo a
thorough evaluation including examination of the skin and
MRI imaging of the brain (see Fig. 1). In addition, children
with infantile spasms from TSC can usually be very
successfully treated with the medication vigabatrin [6].
This drug raises brain levels of GABA, the main inhibitory
neurotransmitter of the cerebral cortex. In contrast to other
causes of infantile spasms, the rapid and usually complete
response to vigabatrin suggests that infantile spasms in TSC
may be due to abnormalities of GABAergic interneurons.
This potential mechanism is of great interest as current
theories of the pathogenesis of both epilepsy and autism in
the general population prominently feature abnormalities of
GABAergic interneuron differentiation and/or function [7].
The very high prevalence of epilepsy makes any
assessment of neurodevelopmental disorders in patients
with TSC particularly challenging and raises several
questions. Are patients actively having seizures? If so,
how often and from what region of the brain? Are there
cognitive or other side effects from medications used to
treat seizures? Despite these confounding factors, epilepsy
alone does not account for all problems in TSC and
demands further inquiry to determine why neurological
comorbidities are seen at such high rates [8].
Autism
The association of autistic behaviors with TSC was first noted
many years ago ([9] and see section below). Using detailed
assessments, a diagnosis of autism is seen in approximately
25% of patients and an autism spectrum disorder (ASD) in
another 25% [10, 11]. Of note, autism and ASD are
commonly seen in conjunction with epilepsy in patients
with TSC though this is not an absolute association.
Furthermore, autism and ASD in TSC are seen in males
and females at similar rates standing in marked contrast to
the male predominance seen in the general population with
autism [12]. The association of autism in patients with TSC
remains poorly understood but may be impacted by seizures
at a young age, the presence and location of cortical
malformations, abnormalities of cellular signaling pathways
or other mechanisms that are currently unknown. This
intimate relationship between TSC and autism will be
Fig. 1 Skin and brain abnormalities in patients with TSC. a Facial
angiofibromas are found in many children with TSC. While they
begin as flat red macules on the face, they progress to raised red
papules (*) that tend to spread over the cheeks and nose in a
distinctive manner. b Shagreen patches (raised irregular skin lesions)
are often found on the lower back. They are not usually seen in young
children but can be a specific sign of TSC in older children and adults.
c Hypopigmented macules (Ash Leaf spots) are the most common
skin abnormality in TSC and can be seen even at birth. The typically
have an irregular appearance with most patients having >5 lesions. d
FLAIR (Fluid Inversion Recovery) MRI images of the brain show
both tubers (black arrows) and SEN (white arrows). Patient photo-
graphs by author obtained with consent
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findings that may pertain to the general population of
children with autism who do not have TSC.
Additional neurological manifestations
Children with TSC have developmental delay that typically
manifests during the first year of life. As they age, frank
mental retardation withpermanent cognitive deficitsisseenin
approximately one-half of patients with TSC [13]. Behavioral
problems are also seen in many children with TSC and can
be very challenging for caregivers. Even children who
appear to have normal or near normal intelligence often
have exaggerated presentations of normal childhood behav-
iors. Other aspects of TSC not adequately recognized
include anxiety disorders and depression that are frequently
seen in young adults and adults with TSC irrespective of a
history of cognitive delay or autism [14].
Despite this sobering description of the neurological
manifestation of TSC, it should be kept in mind that 25–
40% of patients with TSC have normal to near normal
intelligence and function quite well [15]. Why such
variability exists in TSC is not well understood but as
detailed below remains an active area of research.
Non-neurological manifestations
In addition to brain, other organs are prominently involved
in TSC. As befitting a neurocutaneous disease, skin
involvement is very common and often leads clinicians to
suspect the correct underlying diagnosis. Hypopigmented
macules (also known as Ash Leaf spots) are seen in many
patients with TSC (Fig. 1c). While not specific to TSC,
even at birth multiple hypopigmented regions can be seen
in very young children. However, they can be seen more
readily after sun exposure to the normal appearing skin as
hypopigmented macules usually do not tan. A Wood’s light
(UV) can also be employed in the clinic to aid in the
identification of hypopigmented macules but in the opinion
of the author this tool does not appreciably increase the
sensitivity of detection. Other dermatologic manifestations
include Shagreen patches (Fig. 1b) and angiofibromas
(Fig. 1a, originally termed “adenoma sebaceum”). Shagreen
patches are raised areas of the skin usually found in the
lower part of the back and are relatively specific for TSC.
Facial angiofibromas are often progressive lesions in older
children and adults that can cause cosmetic as well as
medical problems given their propensity to bleed. Overall,
these skin manifestations are a minor aspect of the disease
but their recognition can be critical for a correct underlying
diagnosis and focusing attention to the potentially more
severe manifestations of TSC.
Finally, patients with TSC often have abnormalities of
heart, kidney and lung. Each of these manifestations has
complex presentations that are beyond the scope of this
review but have recently been thoroughly reviewed [2].
Historical overview of TSC
TSC has a relatively long history in the annals of medicine
with important gains by numerous investigators (well
summarized in [16]). TSC was initially reported in 1863
by Friedrich Daniel von Recklinghausen. Though he is
best remembered for his later descriptions of neuro-
fibromatosis, he is credited for the first report of
hard (sclerotic) areas of the brain as well as heart tumors
in a child who died in the neonatal period [17]. von
Recklinhausen did not however recognize these abnormali-
ties as a specific disorder. It was left to Désiré-Magloire
Bourneville who between 1880 and 1900 published multiple
reports that defined a distinct pathological entity in patients
suffering from developmental disabilities and epilepsy [18,
19]. Like most medical therapies of this period, treatment
options were limited for patients with epilepsy but included
bromides, nitrates and even leeches! These therapies
evidently were quite ineffective as Bourneville went on at
autopsy to describe focal brain lesions in these patients.
These lesions were evidently reminiscent of small potatoes
(“tubers”) leading Bourneville to coin the somewhat awk-
ward term “sclérose tubéreuse” or tuberous sclerosis [18]. In
addition to brain involvement, Bourneville also described
associated abnormalities of kidneys and skin. This constel-
lation of clinical findings were further expanded by Vogt in
1908 who suggested tuberous sclerosis be diagnosed in
patients with developmental delay, epilepsy and cutaneous
signs of “adenoma sebaceum” [20]. Of note, this so called
“Vogt’st r i a d ” held sway for many years in the general
perception and diagnosis of TSC. More recent studies have
found that only about 30% of all patients actually fulfill
these criteria underscoring an appreciation for the protean
manifestations of TSC [21, 22]. Incremental gains in the
understanding of tuberous sclerosis continued during the
20th century but was revitalized by Gomez in the 1960’sa n d
1970’s[ 23]. His studies greatly organized this field and
paved the way for the development of molecular tools to
define genetic etiologies that underlie tuberous sclerosis. Of
note, the nomenclature also evolved over time with the
extension “complex” added to emphasize the multi-organ
nature of the disease and also distinguish it from the
unrelated disorder multiple sclerosis [24]. The name tuber-
ous sclerosis complex also serendipitously reflects contem-
porary knowledge that the TSC1 and TSC2 gene products
function together as a complex and also inhibit the multi-
protein complex mTORC1 (see below, Fig. 2).
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Charles J.C. Earl (National Hospital, Queen Square
London) in 1932 published a remarkable description of 29
patients with TSC [9]. This report describes quite well the
clinical symptoms of what is now recognized as autism and
autism spectrum disorders (ASD). Patients were reported to
“appear vague and preoccupied and is mentally inaccessible”
and “Speech which may have been fairly fluent now falls off,
they use very few words and may show echolalia and short
perseverative repetition of phrases, or may become almost
entirely mute”. Remarkably, these words were written at
least 10 years before Leo Kanner first published his
landmark study using the word autism to describe children
with similar symptoms [25].
Neuropathology
Tubers
Tubers are quite readily detectable using modern MRI
making the correct diagnosis of TSC fairly straightforward
for most patients (Fig. 1d, tubers black arrows). Micro-
scopic evaluation of tubers reveals many abnormal and
large cells that express markers of both neuronal as well as
glial cell differentiation [26]. These and other findings
suggest that the TSC genes normally function during neural
progenitor cell differentiation and regulate the production
of both neurons and glial cells.
While gross and microscopic abnormalities have been
reported in brains from patients with TSC for many years,
there are still many questions about over how these lesions
form and contribute to the neurological phenotypes that are
seen. The consensus view is that tubers are responsible for
cognitive impairment, seizure generation, behavioral dis-
turbances and autism. There is some controversy about this
point at least for seizure generation as tubers themselves
can be electrically silent though abnormal discharges can be
seen emanating from the immediately adjacent cortex [27].
Tubers arise during early brain development prior to
18 weeks of gestation; this has been substantiated by two
autopsy studies of aborted human fetuses with TSC [28, 29].
Tubers should then considered to be cortical malformations
that arise only during early fetal development and not
postnatally. This view has been challenged by anecdotal
reports of changes in the MRI appearance of tubers in
children and adults with TSC. In addition to possible
structural changes, tubers may alter epileptogenicity over
time with previously quiescent lesions becoming sites of
seizure origination.
The relationship of tubers to overall function, epilepsy
and autism has been extensively studied though the
published literature is not coherent with many contradictory
studies. For example, autism was found to be highly
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Fig. 2 Simplified Upstream and Downstream Signaling Pathways in
TSC. Growth factors (not shown) bind to transmembrane receptors
and lead to PI-3 Kinase activity causing an increase in PIP3
production leading to activation of AKT. AKT and/or ERK can then
directly inhibit tuberin by phosphorylation. However, phosphorylation
of tuberin by AMPK at other amino acid residues is activating.
Hamartin binding seems to be required for stabilization and function
of tuberin. Tuberin contains a C terminal GAP (GTPase activating
protein) domain that inhibits the G protein Rheb, an important
activator of mTORC1. Intermediary steps are not completely
understood but may involve binding of FKBP38 [70] and/or
enzymatic activity of PLD1 [71]. Loss of hamartin or tuberin function
by mutation or inhibitory phosphorylation then allows constitutive
activity of mTORC1 with subsequent increases of levels of phosphor-
ylated ribosomal S6-kinase and phosphorylated ribosomal S6. How
these alterations lead to the specific pathological changes in TSC is
not well understood. Rapamycin (Rapa) and similar drugs potently
inhibit mTOR activity within mTORC1. ATP indicates sites of
phosphorylation by kinases. Figure modified from [72]
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with patients with a history of temporal lobe seizures [30,
31]. This finding has not been replicated by other groups
[32] though a strong association of cerebellar tubers with
autism was noted [33, 34]. These discordant findings
strongly suggest that other factors in addition to location
of tubers determine the development of complex disorders
such as autism. An important example is the growing body
of work using mouse models of TSC that suggests that
tubers are not required for neurological dysfunction. Using
several “tuber-less” mouse models (see below) loss of Tsc1
or Tsc2 has recapitulated several important aspects of the
TSC phenotype including epilepsy, cognitive problems and
social impairment. These findings are difficult to reconcile
with the overt brain abnormalities seen in the vast majority
of patients with TSC. Additional animal models and
technical approaches then are likely needed to define the
primacy of tubers in the pathogenesis of tuberous sclerosis.
SEN, SEGA
In addition to cortical tubers, other structural brain lesions in
TSC include subependymal nodules (SEN) (Fig. 1d, white
arrow) and subependymal giant cell astrocytomas (SEGAs)
(also known as a subependymal giant cell tumor, SGCT). As
their names imply, these lesions are found immediately
subjacent to ependymal layer lining the ventricles of the
brain. SEN and SEGAs are likely very similar pathological
entities that differ mainly by relative size and a propensity of
SEGAs to grow. While they can be found throughout the
lateral and third ventricles, they have a tendency to grow
near the Foramen of Monro and become clinically important
if continued growth in this region obstructs the flow of CSF
leading to hydrocephalus. Fortunately, SEGAs are generally
quite slow growing and can usually be identified by serial
brain imaging prior to the development of hydrocephalus or
other symptoms. Interestingly, SEGAs exhibit a limited
window of growth that is almost always restricted to the
first two decades of life. Analyses of SEGAs reveal
expression of both neuronal and glial cell markers reminis-
cent of tubers [35, 36]. The expression of glial cell markers
however, predominates in SEGAs. While speculative, this
may reflect their postnatal origin from neural progenitors that
normally reside in the subependymal zone [37].
Molecular genetics
A genetic basis for TSC was first noted in 1913 by H. Berg
who described multiple affected member of an individual
family [38]. Additional pedigrees established an autosomal
dominant pattern of transmission though the majority of
patients appear to have a sporadic form of TSC. However,
like many diseases, major advances in understanding TSC
only occurred after the identification and cloning of the
causative genes. Initial linkage studies using familial cases
identified two independent loci on chromosomes 9 and 16.
The subsequent cloning of TSC1 (encodes hamartin) [39]
and TSC2 (encodes tuberin) [40] genes and protein
interaction studies led to the current model where hamartin
and tuberin are obligate partners with both proteins required
for full inhibition of downstream targets (see Fig. 2). TSC1
and TSC2 both encode large proteins that have extensive
sequence conservation in widely divergent species. This
suggests that there are other hamartin and tuberin specific
functions that are not yet known. With this caveat, the
current model of hamartin/tuberin function predicts that
patients with TSC1 or TSC2 mutation should have similar
disease manifestations from loss of function of the entire
hamartin/tuberin complex. While this is broadly true,
patients with TSC2 mutations tend to have a more severe
clinical course and are much less likely to have a family
history of TSC [41]. Currently,amajorissueinTSCresearch
is whether the focal abnormalities in various organs originate
from loss of the second allele of either the TSC1 or TSC2
gene. This would then be similar to the “two-hit” model of
tumor suppressor function put forth by Knudsen [42] and
like retinoblastoma suggests that while transmittable as an
autosomal dominant disorder, it is autosomal recessive at the
cellular level. Support for such a model has been defini-
tively shown for kidney tumors in TSC but has been much
more difficult to show in brain lesions [43]. This has led to
speculation that cells with second hits are either very
difficult to detect in tubers and SEGAs or that distinctive
mechanisms of tuberin or hamartin inactivation including
phosphorylation are at work in the brain. An additional
possibility is that loss of one copy of either gene is sufficient
to cause disease. This model of haploinsufficiency would
predict hamartin/tuberin loss of function in every cell of the
body including those in the brain. This last model is not
congruent with clinical findings as focal brain lesions are
always found adjacent to normal appearing cortex (see
Fig. 1d). However, animal models have provided some
support for haploinsufficiency as mice with one functional
allele of the Tsc1 or Tsc2 genes have learning abnormalities
in the absence of tuber-like lesions [44, 45].
Signaling pathways
While advances in molecular genetics transformed the field
of TSC, the greatest catalyst was the placement of hamartin
and tuberin within cellular signaling pathways. This work
depended on the use of simpler model systems including
yeast and Drosophila to identify hamartin/tuberin as
upstream regulators of Rheb and mTOR (reviewed in
J Neurodevelop Disord (2009) 1:141–149 145[46]). These findings were rapidly confirmed in mammalian
tissues and cells and extended to identify complex
regulatory pathways with multiple upstream and down-
stream kinases (Fig. 2). These cascades culminate to control
mammalian target of rapamycin (mTOR). This serine/
threonine kinase was already known to be a critical
regulator of many important cellular processes [47]. mTOR
is found with other defined binding partners as mTOR
Complex 1 (mTORC1) or mTOR Complex 2 (mTORC2)
that have distinct functions [48]. Of note, mTORC1 is
potently inhibited by rapamycin while mTORC2 is much
less sensitive. mTORC1 inhibitors have thus garnered much
attention as possible new and rational therapeutics for TSC.
While the assignment of hamartin and tuberin to specific
signaling pathways is a major advance, it is still unclear
how such alterations lead to the complex neurologic and
non-neurologic manifestations seen in TSC. Downstream of
mTORC1, activated phosphorylated-S6 kinase and
phosphorylated-S6 regulate the translation of subsets of
mRNAs. Loss of hamartin or tuberin may then cause
dysregulated mRNA translation with a subset of these
genes responsible for the phenotypes seen in TSC. Much
more research is needed to identify genes regulated by
TSC1/TSC2 and how their specific dysfunction affects brain
development and homeostasis.
Animal models
The generation of rodent models was a critical advance to
determinemanyfacetsofdiseaseinitiationandprogressionin
TSC. As this review focuses on human neurodevelopmental
disorders in TSC, animal models will not be discussed in
great detail. However, recent reviews are available [27, 49].
Conventional knockout of the Tsc1 and Tsc2 genes in
mice clearly established essential roles for both genes
during embryonic development as early demise was seen
prior to any substantive brain development [50, 51]. Further
support for these findings comes from analyses of the Eker
rat, a well studied model for kidney tumorigenesis. The
Eker rat has a high penetrance of kidney tumors and is due
to the heterozygous inactivation of the rat Tsc2 gene [52].
Similar to mice, rats with homozygous loss of their Tsc2
gene have an early embryonic lethal phenotype.
The generation of conditional knockout (CKO) mice
using the Cre-LoxP system was used to determine the
contribution of the Tsc1 gene to brain development.
Tsc1
GFAP CKO mice were produced by inactivation of the
Tsc1 gene in astrocytes [53] while Tsc1
Synapsin CKO [54]
and Tsc1
CamKII CKO mice [45] have Tsc1 gene inactivation
restricted to post-mitotic neurons. Additional models using
this approach are needed. For example, the dramatic
response of infantile spasms to vigabatrin in patients with
TSC suggests an underlying abnormality of GABAergic
interneurons. Future animal models targeting these critical
neurons may offer much insight to the pathogenesis of
these often devastating seizures.
In addition to Tsc1 models described above, the
conditional knockout of the mouse Tsc2 gene in the brain
was recently published [55]. This animal model also used
the Cre-LoxP system to target neural progenitor cells. The
mice had abnormalities of cortical development involving
both neuronal and glial cell lineages. Increased mTORC1
activity was also seen.
Animal models have been invaluable for determining the
contribution of the Tsc1 and Tsc2 genes to specific lineages
of the brain and for preclinical testing of new therapeutics
(see below). They do not however recapitulate many
aspects of TSC including tuber or SEGA formation. It is
not known is this is due to species-specific functions of the
TSC genes in human versus mouse or whether the targeted
populations of neural cells and/or the timing of gene
inactivation are not optimal.
Preclinical trials of mouse models with mTORC1
inhibitors
The development of robust preclinical models of TSC
coupled with assignment of hamartin/tuberin to control of
mTORC1 activity quickly led to the hypothesis that
treatment with rapamycin or similar agents could halt or
even reverse the abnormalities seen in TSC. Tsc1
GFAP CKO
mice are very well suited to test this hypothesis as their
seizures increase in frequency over time and are linked with
abnormalities of glutamate and potassium uptake from the
synaptic cleft by astrocytes [56, 57]. These findings
strongly support the role of astrocytes in epileptogenesis
and also suggest similar abnormalities may exist in human
tissues as well [58]. Zeng et al. treated Tsc1
GFAP CKO mice
with rapamycin and found prolongation of lifespan and a
striking decrease in the number of seizures compared to
Tsc1
GFAP CKO mice treated only with vehicle [59]. This
was seen if rapamycin was used before or even after seizure
initiation suggesting that mTORC1 inhibition may act like a
true “anti-epileptic” in this mouse model. This group
further demonstrated that rapamycin treatment restored
glutamate homeostasis with an increase in the expression
of the astrocytic glutamate transporters, GLT-1 and GLAST.
Withdrawal of rapamycin was associated with a return of
symptoms and eventual demise of these mice. This suggests
that if mTORC1 inhibitors become a viable therapy for
patients with TSC, these drugs may need to be given
continuously or in cycles.
Tsc1
Synapsin CKO mice were also treated with rapamycin
or RAD001, a related mTORC1 inhibitor [60]. Use of
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activity to levels seen in control brains. Furthermore,
treatment with mTORC1 inhibitors restored AKT activation
in the brains of Tsc1
Synapsin CKO mice. This is an important
finding as TSC1 or TSC2-deficient cells have impaired
AKT activation due to loss of mTORC2 activity [61]. As
activated AKT is a potent human oncogene, these findings
may explain why the tumors seen in TSC are not malignant.
The clinical use of mTORC1 inhibitors should then be
viewed with some caution as this result suggests that
mTORC1 inhibition may activate AKT and promote
tumorigenesis. It should be stressed that this remains a
theoretical concern for mTORC1 inhibitors that is not
supported by any data from mouse models or when used by
patients with TSC.
Finally, Tsc2 heterozygous conventional knockout mice
were used to assess problems in learning and whether such
abnormalities are mTORC1-dependent by response to
rapamycin [45]. Tsc2
+/− mice do not have overt cortical or
hippocampal structural abnormalities though a moderate
increase in mTORC1 was seen. These findings in Tsc2
+/−
mice were correlated with behavioral studies showing
impaired long term potentiation and deficiencies in
hippocampus-dependent spatial memory assayed in the
Morris water maze. Remarkably, rapamycin treatment
normalized long term potentiation and restored spatial
memory. These results suggest that even partial dysregula-
tion of mTORC1 through haploinsufficiency may lead to
cognitive deficits in patients with TSC and that even tuber-
less regions of the brain may contribute to neurological
dysfunction. Similar results were previously reported in
Tsc1 heterozygous conventional mice though reversibility
through mTORC1 inhibition was not tested [44]. A recent
report of rapamycin efficacy in mice with a neuronal loss of
Pten (see Fig. 2) further supports than even in the absence
of discrete cortical lesions, dysregulation of TSC/Rheb/
mTOR signaling can cause cognitive and social abnormal-
ities [62].
Clinical trials with mTORC1 inhibitors
While therapies for patients with TSC have certainly
progressed over the last century, we are still largely
restricted to symptomatic treatment of epilepsy, autism,
psychiatric disorders and mental retardation. As described
above, identification of hamartin/tuberin in the control of
mTORC1 signaling almost immediately led to the sugges-
tion that rapamycin or related agents would be logical
therapies to treat and possibly even prevent the severe
neurological aspects of TSC. Application of rapamycin and
RAD001 to preclinical animal models has further increased
enthusiasm for such use.
Rapamycin (sirolimus) has been approved by the FDA
since 1999 for immunosuppression in patients receiving
kidney transplants. It has recently been used with adults
who have kidney and lung manifestations of TSC or
lymphangioleiomyomatosis (LAM), a genetically related
disorder arising from somatic mutations in the TSC2 gene
[63]. In these adult patients with TSC or LAM, kidney
angiomyolipomas regressed in size and patients with lung
disease appeared to have a stabilization of their disease
compared to clear progression in patients treated with a
placebo [64, 65]. Side effects were generally benign and the
drug was overall well tolerated.
To date, there have been two reports of rapamycin use
for neurological disease in patients with TSC [66, 67]. Both
studies reported SEGA regression, likely circumventing the
need for any neurosurgical intervention. These patients
were younger than those in the TSC kidney and lung trials
but also appeared to tolerate rapamycin therapy well.
These initial clinical results in kidney, lung and brain
lesions were very promising and seem to validate their
potential use in patients with TSC. However, all treatments
with mTORC1 inhibitors reported to date were applied to
progressive lesions that likely originated after birth. It is not
known if mTORC1 inhibition can reverse abnormalities
related to tubers and other abnormalities that arose during
fetal development. However even if tubers are static
structural lesions, the identification of altered glutamate
homeostasis in Tsc1
GFAP CKO mice for example raises the
intriguing possibility that functional status of tubers to
cause neurological disease may still be reversible through
inhibition of mTORC1.
Summary and future directions
Amazing progress has been recently made in TSC research.
However, fundamental questions about the relationship of
TSC to neurodevelopmental disorders remain. Is autism and
ASD in TSC due to the number or location of tubers? Are
tubers even required for disease pathogenesis? Do seizures
at a young age trigger autistic symptoms? Does loss of even
one copy of the TSC1 or TSC2 genes cause neurological
dysfunction due to haploinsufficiency? Is a “second hit”
necessary in key brain regions to cause autism or epilepsy?
The answers to these and other questions remain active
areas of investigation and will require more sophisticated
animal models of TSC and translational research to fully
define the mechanism of abnormal brain development.
Finally, are findings from TSC relevant to the millions of
people worldwide with neurodevelopmental disorders that
do not have TSC? It is possible that a shared mechanism of
disrupted mTOR signaling may explain the significant
overlap between patients with TSC and patients with
J Neurodevelop Disord (2009) 1:141–149 147autism or epilepsy. This intriguing possibility has received
scant attention though variations in genes involved in
phosphatidylinositol/mTOR signaling (INPP1, PIK3CG,
TSC2) have been identified in children with autism [68].
Direct evidence for involvement of this pathway in the
brains of children with autism is lacking though the existing
data is limited to one series of 5 patients examined for
phosphorylated-S6 levels in postmortem frontal cortex and
cerebellum [69]. Further experiments exploring mTOR
signaling abnormalities in patients with isolated autism or
epilepsy need to be undertaken. If such abnormalities exist,
clinical trials using mTORC1 inhibitors may establish new
therapeutic approaches for these devastating disorders.
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